Evidence map›Paper›PMID 33138825›Full record

ArticleBMC veterinary research2020

Novel biotechnological approaches for monitoring and immunization against resistant to antibiotics Escherichia coli and other pathogenic bacteria.

José E Belizário, Marcelo P Sircili

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

José E BelizárioDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Av. Lineu Prestes, 1524, São Paulo, SP, CEP 05508-900, Brazil. josebelizario223@gmail.com.ORCID http://orcid.org/0000-0002-3832-5279
Marcelo P SirciliLaboratory of Genetics, Butantan Institute, Av. Vital Brazil, 1500, São Paulo, SP, CEP 05503-900, Brazil.
Instituto Butantan · BRUniversidade de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 486048/2011 and 312206/2016-0Fundação de Amparo à Pesquisa do Estado de São Paulo 10/06707-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/02497-7, 2014/20847-0
6 · The paper itself

Abstract

The application of next-generation molecular, biochemical and immunological methods for developing new vaccines, antimicrobial compounds, probiotics and prebiotics for zoonotic infection control has been fundamental to the understanding and preservation of the symbiotic relationship between animals and humans. With increasing rates of antibiotic use, resistant bacterial infections have become more difficult to diagnose, treat, and eradicate, thereby elevating the importance of surveillance and prevention programs. Effective surveillance relies on the availability of rapid, cost-effective methods to monitor pathogenic bacterial isolates. In this opinion article, we summarize the results of some research program initiatives for the improvement of live vaccines against avian enterotoxigenic Escherichia coli using virulence factor gene deletion and engineered vaccine vectors based on probiotics. We also describe methods for the detection of pathogenic bacterial strains in eco-environmental headspace and aerosols, as well as samples of animal and human breath, based on the composition of volatile organic compounds and fatty acid methyl esters. We explain how the introduction of these low-cost biotechnologies and protocols will provide the opportunity to enhance co-operation between networks of resistance surveillance programs and integrated routine workflows of veterinary and clinical public health microbiology laboratories.

Indexed as

BiotechnologyDrug Resistance, BacterialAnimalsAnti-Bacterial AgentsBacteriaBacterial InfectionsChickensEnterotoxigenic Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesHumansProbioticsVirulence FactorsAnti-Bacterial AgentsEscherichia coli VaccinesVirulence FactorsAnd FAMEsAntibioticsBacterial vaccinesMicrobiomesProbioticsVOCs

Identifiers

PMID33138825
PMCPMC7607641
OpenAlexW3096202029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.